Comparing the current results to its competitors, Vaxart Inc reported Revenue decrease in the 2 quarter 2026 year on year by -31.58 %, faster than the overall decrease of Vaxart Inc 's competitors by -13.17 %, recorded in the same quarter.
Vaxart Inc 's Comment on Competition and Industry Peers
The company operates in the pharmaceutical and vaccine industries, which are highly competitive sectors. Competition arises from biotechnology and pharmaceutical companies, academic institutions, government agencies, and public and private research institutions. Competitors focus on improving existing therapies, vaccines, and delivery methods, as well as developing new products. The company expects competition to intensify with the introduction of new vaccines and advanced technologies. Its tablet or oral delivery vaccine candidates will compete based on efficacy, safety, convenience, price, availability, generic competition, and reimbursement. Commercial opportunities may be diminished if competitors develop products that are safer, more effective, more convenient, or less expensive.
September 10, 2025
Promising Developments Despite Financial Hurdles: Vaxart’s Advancements in Norovirus Vaccine ResearchIn the complex landscape of pharmaceuticals and vaccine development, financial metrics often cast a long shadow over the innovative strides made by companies. Vaxart Inc, a biotechnology firm known for its diverse pipeline of orally administrable vaccines, is a representative case. Although financial figures report a cumulative net loss of $57 million for the year ending in the second quarter of 2025, coupled with a disheartening negative return on assets (ROA) of -38.73%, the scientific achievements of Vaxart deserve a closer look. Within the healthcare sector, no less than 416 companies have recorded a ...
April 30, 2024
for CSIMarket.com :In recent developments in vaccine research, Vaxart has announced positive results for its bivalent norovirus vaccine candidate in lactating mothers. This breakthrough suggests a potential pathway to protect vulnerable infants from the highly contagious and often severe norovirus infection. This article aims to outline the factual evidence from Vaxart s study and interpret its implications for future prevention strategies against norovirus. Summary:Vaxart s study focused on lactating mothers who were administered the bivalent norovirus vaccine candidate. The researchers observed a significant rise in antibodies not only in the mothers themselves but also in their breast milk. These findin...
Windtree Therapeutics Inc is a biotechnology company that develops novel gene therapies to treat respiratory diseases by delivering therapeutic proteins to the lungs. They aim to address unmet medical needs and improve the lives of patients through their innovative treatment approaches.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
Inovio Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of immunotherapies for the treatment of various diseases, including cancers and infectious diseases. Their business model involves leveraging their proprietary platforms, such as DNA-based technology and electroporation, to design and develop novel vaccines and therapies which are then advanced through clinical trials and potential partnerships for further commercialization.
Sources:
Vaxart Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Vaxart Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
